After the "Glass Gel Battle," Juzhi Biotech shows signs of growth anxiety

Ask AI · Can JezzBio’s beauty-medical layout become the key to its comeback in 2026?

In mid-2025, an “industry-level public-opinion controversy” involving Huaxi Biologics pushed JezzBio onto the center stage.

This dispute was not only a battle over discourse power in the two leading tracks—recombinant collagen and hyaluronic acid—but also drew JezzBio into a public-opinion storm over alleged overstatement of the collagen content in its core brand, “Kefumei.”

Although the storm ultimately ended with detection results differing due to different testing standards, it also, to a certain extent, affected JezzBio’s performance.

Combined with increasingly fierce industry competition, JezzBio delivered a 2025 report card showing declines in both revenue and profit: revenue for the period was 5.518 billion yuan, down slightly by 0.37% year over year; net profit was 1.914 billion yuan, down 7.15% year over year.

Looking at specific business segments, JezzBio’s core brand lineup showed clear separation in 2025:

As the absolute mainstay contributing more than 80% of revenue, Kefumei achieved sales revenue of 4.470 billion yuan in 2025, down 1.6% year over year.

The financial report states that this was mainly driven by external shocks and intensifying industry price competition.

Judging from the public-opinion controversy that erupted in mid-2025, challenges to the claimed compliance of Kefumei products to some extent weakened consumer trust, causing a substantive impact on sales of this flagship brand.

However, the skincare brand “KeliGold” still maintained a growth trajectory, recording revenue of 918 million yuan in 2025, up 9.2% year over year.

This was mainly due to active expansion of online channels, as well as the successful launch of the celebrity flagship product “Big Film King 3.0” after an iterative upgrade.

After the pains experienced in 2025, JezzBio has clearly stated its goal for 2026: “return to growth.”

Based on the strategic layout revealed in its financial report, JezzBio’s future core growth points are mainly focused on increasing investment in beauty-medical business, adding new ingredient applications beyond collagen, incubating new brands, and expanding across all channels.

Perhaps the most compelling move is the beauty-medical business.

Since 2025, JezzBio’s products—recombinant type I a1 subtype collagen lyophilized fibers, recombinant type I a1 subtype collagen, and a compounded solution of sodium hyaluronate—have obtained approvals from the National Medical Products Administration and have been successively launched. This marks that it has officially opened up the beauty-medical market.

The “glass-and-gel battle” of 2025 was not only a public-relations crisis, but also like an industry “coming-of-age ceremony,” exposing JezzBio’s shortcomings on the run and prompting it to catch up on product standards and compliance.

In 2026, with JezzBio holding “trump cards” across three categories of medical devices, can it leverage the beauty-medical track to successfully stage a comeback, regain a high-growth rhythm, and win back momentum? The market is watching closely.